We are a multi-laboratory group, covering a full spectrum from gene array to population-based study, including patient-reported outcomes and toxicity clustering. The core group operates animal models of chemotherapy-, radiotherapy- and targeted therapy-induced mucositis, and tests drugs and compounds that may alleviate or prevent symptoms of mucositis.
Professor Keefe works with various pharmaceutical companies on drug development in mucositis. Senior members of this group have been very closely involved with recent updates of clinical guidelines and systematic reviews for the Multinational Association of Supportive Care in Cancer (MASCC).
To support research in the Mucositis Research Laboratory at the Hanson Institute, please contact the Royal Adelaide Hospital Research Fund.